Significant Ownership of John D. Halpern
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for John D. Halpern focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
CIK context first
Continue from John D. Halpern
Significant Ownership of John D. Halpern
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| ERNA | Eterna Therapeutics Inc. | Common Stock, par value $0.005 per share | 9.6% | $1,254,084 | +$175,402 | 5,971,830 | +16% | John D. Halpern | 31 Mar 2025 |
| ERNA | Ernexa Therapeutics Inc. | Common Stock, par value $0.005 per share | 5.6% | $13,350 | 66,751 | John D. Halpern | 10 Feb 2026 |
Schedules 13D/G Reported by John D. Halpern:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.